Thermo Fisher Scientific Inc. (ETR:TN8)

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Life Sciences Solutions Revenue	10.37B	9.63B
Life Sciences Solutions Revenue Growth	7.71%	-3.47%
Analytical Instruments Revenue	7.55B	7.46B
Analytical Instruments Revenue Growth	1.22%	2.75%
Specialty Diagnostics Revenue	4.68B	4.51B
Specialty Diagnostics Revenue Growth	3.64%	2.43%
Laboratory Products and Biopharma Services Revenue	23.98B	23.16B
Laboratory Products and Biopharma Services Revenue Growth	3.57%	0.50%
Revenue (Other)	-2.03B	-1.88B
Revenue (Total)	44.56B	42.88B
Revenue (Total) Growth	3.91%	0.05%

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Consumables Revenue	18.66B	17.59B
Consumables Revenue Growth	6.12%	-0.06%
Instruments Revenue	7.30B	7.45B
Instruments Revenue Growth	-1.95%	-2.62%
Services Revenue	18.59B	17.85B
Services Revenue Growth	4.19%	1.31%
Revenue (Total)	44.56B	42.88B
Revenue (Total) Growth	3.91%	0.05%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
North America Revenue	23.03B	22.50B
North America Revenue Growth	2.35%	-1.14%
Europe Revenue	11.83B	10.86B
Europe Revenue Growth	8.92%	1.08%
Asia-Pacific Revenue	8.10B	7.96B
Asia-Pacific Revenue Growth	1.82%	1.05%
Other Regions Revenue	1.60B	1.56B
Other Regions Revenue Growth	2.31%	5.54%
Revenue (Other)	-1.00M	1.00M
Revenue (Total)	44.56B	42.88B
Revenue (Total) Growth	3.91%	0.05%

EBIT

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Life Sciences Solutions Operating Income	3.77B	3.50B
Life Sciences Solutions Operating Income Growth	7.56%	2.43%
Analytical Instruments Operating Income	1.74B	1.96B
Analytical Instruments Operating Income Growth	-11.20%	2.46%
Specialty Diagnostics Operating Income	1.26B	1.16B
Specialty Diagnostics Operating Income Growth	8.37%	3.11%
Laboratory Products and Biopharma Services Operating Income	3.35B	3.09B
Laboratory Products and Biopharma Services Operating Income Growth	8.41%	-7.98%
Operating Income (Other)	-2.36B	-2.37B
Operating Income (Total)	7.75B	7.34B
Operating Income (Total) Growth	5.57%	6.97%

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Total Organic Revenue Growth	2.00%	-

Updated Dec 31, 2025. Data Source: Fiscal.ai.